# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2024

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2024-08-09
- Accepted by EDGAR: Aug 9, 2024, 20:45 ET
- Period: 2024-06-30
- Accession: 0001477932-24-004635
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000147793224004635/celz_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000147793224004635/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-04-01 to 2024-06-30 | $8.0k | us-gaap:Revenues |
| Revenue | 6 months, 2024-01-01 to 2024-06-30 | $8.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2024-04-01 to 2024-06-30 | $3.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2024-01-01 to 2024-06-30 | $3.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2024-04-01 to 2024-06-30 | $4.8k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2024-01-01 to 2024-06-30 | $4.8k | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-04-01 to 2024-06-30 | $924.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2024-01-01 to 2024-06-30 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2024-04-01 to 2024-06-30 | $676.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2024-01-01 to 2024-06-30 | $1.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-04-01 to 2024-06-30 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-01-01 to 2024-06-30 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-04-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-01-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-04-01 to 2024-06-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-01-01 to 2024-06-30 | −$2.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months, 2024-01-01 to 2024-06-30 | −$2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 6 months, 2024-01-01 to 2024-06-30 | $149.5k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | at 2024-06-30 | $7.6m | us-gaap:AssetsCurrent |
| Total assets | at 2024-06-30 | $8.0m | us-gaap:Assets |
| Current liabilities | at 2024-06-30 | $376.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-06-30 | $376.3k | us-gaap:Liabilities |
| Shareholders' equity | at 2024-06-30 | $7.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 18,973 characters.

*Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2023, and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.*

### Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

### Overview

We are a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:

15

#### Table of Contents

Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities.

We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at eight locations in the United States.

In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz™ platform (CELZ-100), that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties (or “supercharges” them) providing them with the ability to treat multiple indications. We have validated this ability through the third-party studies described below that were independently conducted on selected human donor patient cells for accuracy and reproducibility. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

In June 2022, we signed an agreement with Greenstone Biosciences Inc. (“Greenstone”) for the development of a human induced pluripotent stem cell (iPSC) pipeline for our ImmCelz™ platform. This project was identified as iPScelz™. The efforts by Greenstone are expected to complement and expand our current work on novel therapeutic cell lines. In May 2023, we announced that we had received confirmation that Greenstone had successfully developed a human induced pluripotent stem cell (iPSC). We estimate that the development of this cell line will save the Company two to three years in research and development time along with associated expenses. The final iPScelz™ results in a viral-free cell line which has great potential for differentiation into therapeutic biologics both for the cellular and cell-free programs along with targeted drug discovery. Greenstone’s developments were confirmed by an independent, industry-leading research firm.

In October 2022, we announced the development of our AlloStem™ Clinical Cell Line (CELZ-200), a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File. We believe we will able to use this cell line for many of our programs, including our ImmCelz™ immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, Type I Diabetes (CELZ-201 CREATE-1), AlloStemSpine™ Chronic Lower Back Pain (CELZ-201 ADAPT), and IPScelz™ inducible pluripotent stem cell program in ongoing development with Greenstone.

In November 2022, we announced that the FDA had cleared the Company’s Type I Diabetes (CELZ-201 CREATE-1) Investigational New Drug (IND) application for the treatment of Type 1 Diabetes utilizing our AlloStem™ Clinical Cell Line, which will allow us to begin a Phase I/II clinical trial. The primary objective of the study will be to evaluate CELZ-201 treatment in patients with newly diagnosed Type 1 Diabetes. The trial has also received Institutional Board Review (IRB) approval for the trial to proceed as well as approval of the patient recruitment material. Patient recruitment was initiated in September 2023.

In February 2023, the Company reported positive three-year follow-up data for its StemSpine™ pilot study. The three-year data demonstrates continued efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

16

#### Table of Contents

In March 2023, we reported the following results of independent studies:

- ImmCelz™ (CELZ-100) platform required 75% fewer donor patient cells compared to industry standard.
- The purity of the final ImmCelz™ (CELZ-100) product was greater than 95% compared to the industry standard of greater than 80%.
- ImmCelz™ (CELZ-100) demonstrated a greater than 200% reduction in functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells.
- The ability to verify repeated potency of the final ImmCelz™(CELZ-100) product.

We believe these results show that we will be able to substantially reduce production costs, while allowing for the manufacture of the best clinical product for patients with immune disorders, which will enable us to accelerate our clinical applications and encourage potential collaborations with respect to our ImmCelz™ platform.

In March 2023, the Company announced that it filed an application with the FDA to receive Orphan Drug Designation (“ODD”) for the treatment of Brittle Type 1 Diabetes using its ImmCelz™ (CELZ-100) platform. In March 2024, the Company received ODD for the treatment of Brittle Type 1 Diabetes from the FDA. This designation provides multiple important benefits to support the therapy's development including tax advantages, user fee exemptions, and the opportunity for market exclusivity following approval.

In April 2023, the Company reported positive one-year follow-up data and significant efficacy using CELZ-001 to treat patients with Type 2 Diabetes. There were no safety concerns related to CELZ-001 at one year follow-up utilizing the same infusion procedure as in the currently U.S. FDA cleared Type I Diabetes (CELZ-201 CREATE-1) clinical trial. There were 30 patients in the study, 15 who received CELZ-001 and the rest received optimized medical therapy. At one year, there was an overall efficacy of 93% in the treated patients demonstrating at least a 50% reduction in insulin requirement.

In September 2023, the Company received FDA clearance to initiate a Phase I/II clinical trial of AlloStemSpine™ Chronic Lower Back Pain (CELZ-201 ADAPT) using AlloStem™ (CELZ-201-DDT) for the treatment of lower back pain. The first in country study, which will enroll 30 individuals suffering from chronic lower back pain, is designed to evaluate the safety, efficacy, and tolerability of AlloStem™ (CELZ-201-DDT). The minimally invasive procedure uses ultrasound for the targeted delivery of the cell product, and thus prevents radiation exposure to the patient or the injecting physician. In October, 2023 we filed for and received approval from an institutional review board (IRB) to proceed with this trial. This trial, protected by issued patents, is a huge milestone for the Company and for patients suffering from this debilitating problem and their need for opioids for pain.

In March 2024, the Company secured FDA authorization for an expanded access therapy using CELZ-201, in managing abnormal glucose tolerance and preventing Type I Diabetes in high-risk individuals. The therapy uses CELZ-201 to potentially prevent Type I Diabetes onset and is believed to be a first in medical history. This personalized medicine approach, focuses on a single high-risk patient. CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a Type I Diabetes precursor, at the cellular level.

In June 2024, the Company announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin. The Company believes this development has the potential for not only clinical translation of the human Islet Cells, but also the stand-alone human insulin which is produced by these cells.

During the second quarter of 2024, the Company selected and contracted with the clinical trial site and Contract Research Organization (CRO), initiated the clinical trial site and launched patient recruitment on the Phase I/II clinical trial of AlloStemSpine™ Chronic Lower Back Pain (CELZ-201 ADAPT) using AlloStem™ (CELZ-201-DDT) for the treatment of lower back pain.

***Results of Operations –*** For the Three-months Periods Ended June 30, 2024, and 2023

***Gross Revenue***. There was $8,000 in revenues generated for the three-months ended June 30, 2024 in comparison with **no** revenues for the comparable period a year ago.

17

#### Table of Contents

***Cost of Goods Sold***. There was $3,200 in cost of goods sold for the three-months ended June 30, 2024 in comparison to no cost of goods sold for the comparable period a year ago.

***Gross Profit/(Loss)***. There was $4,800 in gross profits for the three-months ended June 30, 2024 in comparison to no gross profit for the comparable period a year ago.

***Selling, General and Administrative Expenses***. General and administrative expenses for the three-months ended June 30, 2024, totaled $676,086, in comparison with $859,537 for the comparable period a year ago. The decrease of $183,451, or 21% is primarily due to decreases of $67,103 in marketing, $62,049 in marketing-based compensation, $30,736 in Director and Officer (D&O) insurance, and $31,000 in professional fees.

***Amortization Expenses.*** Amortization expenses for the three-months ended June 30, 2024 totaled $29,271 in comparison with $23,021 for the comparable period a year ago.

***Research and Development Expenses***. Research and development expenses for the three-months ended June 30, 2024, totaled $924,749 in comparison to $309,480 for the comparable period a year ago. The increase of $615,269, or 199% was primarily due to increases of $107,021 associated with the CELZ 201 CREATE-1 Type 1 Diabetes clinical trial, $195,792 associated with the CELZ-201 ADAPT Chronic Lower Back Pain clinical trial, and $301,884 in general research and development.

***Operating Loss***. For the reasons stated above, our operating loss for the three-months ended June 30, 2024, was $1,625,306 in comparison with $1,192,038 for the comparable period a year ago.

***Other Income.*** Other income for the three-months ended June 30, 2024, totaled $67,578 in comparison with $89,913 for the comparable period a year ago. The decreased income of $22,335 is due to lower short-term investment balances.

***Net Income/Loss.*** For the reasons stated above, our net loss for the six-months ended June 30, 2024, was $1,557,728 in comparison with a net loss of $1,102,125 for the comparable period a year ago.

***Results of Operations –*** For the Six-month Periods Ended June 30, 2024, and 2023

***Gross Revenue.*** There was $8,000 in revenues generated for the six-months ended June 30, 2024 in comparison with no revenues for the comparable period a year ago.

***Cost of Goods Sold.*** There was $3,200 in cost of goods sold for the six-months ended June 30, 2024 in comparison to no cost of goods sold for the comparable period a year ago.

***Gross Profit/(Loss).*** There was $4,800 in gross profits for the six-months ended June 30, 2024 in comparison to no gross profit for the comparable period a year ago.

***Selling, General and Administrative Expenses.*** General and administrative expenses for the six-months ended June 30, 2024, totaled $1,347,570, in comparison with $1,630,557 for the comparable period a year ago. The decrease of $282,987, or 17% is primarily due to decreases of $122,216 in marketing, $65,167 in public company related expenses, and $112,158 in professional fees.

***Amortization Expenses.*** Amortization expenses for the six-months ended June 30, 2024 totaled $58,542 in comparison with $46,042 for the comparable period a year ago.

***Research and Development Expenses.*** Research and development expenses for the six-months ended June 30, 2024, totaled $1,347,141 in comparison to $628,509 for the comparable period a year ago. The increase of $718,632, or 114% was primarily due to increases of $149,729 associated with the CELZ 201 CREATE-1 Type 1 Diabetes clinical trial, $246,139 associated with the CELZ-201 ADAPT Chronic Lower Back Pain clinical trial, and $312,193 in general research and development.

***Operating Loss.*** For the reasons stated above, our operating loss for the six-months ended June 30, 2024, was $2,748,453 in comparison with $2,305,108 for the comparable period a year ago.

18

#### Table of Contents

***Other Income***. Other income for the six-months ended June 30, 2024, totaled $149,181 in comparison with $151,060 for the comparable period a year ago. The decreased income of $1,879 is due to lower short-term investment balances offset by increased interest rates.

***Net Income/Loss***. For the reasons stated above, our net loss for the six-months ended June 30, 2024, was $2,599,272 in comparison with a net loss of $2,154,048 for the comparable period a year ago.

### Liquidity and Capital Resources

As of June 30, 2024, we had **$7,471,476** of available cash, certificates of deposit and US Treasuries and positive working capital of approximately $7,227,684. In comparison, as of December 31, 2023, we had $9,987,058 of available cash, certificates of deposit and US Treasuries and positive working capital of $9,899,504.

### Cash Flows

***Net Cash used in Operating Activities.*** We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $2,366,168 for the six-months ended June 30, 2024, in comparison to $4,828,379 for the comparable period a year ago, a decrease of $2,462,211 or 51%. The decrease in cash used in operations was primarily related to a $3,000,000 payment of an outstanding accounts payable balance made in the six-months ended June 30, 2023.

***Net Cash Received From Investing Activities.*** Cash received in investing activities was $6,520,191 for the six-months ended June 30, 2024, from the net redemptions of certificates of deposit, in comparison to $497,410 of cash received from net redemptions of certificates of deposit for the comparable period a year ago.

### Net Cash from Financing Activities.

Cash used in financing activities for the six-months ended June 30, 2024 was $149,414 associated with the repurchase of our common stock under our stock re-purchase program. There were no financing activities during the six-months ended June 30, 2023.

### Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles accepted in the United States. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, we review the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

## Controls and procedures

As filed, 1,441 characters.

### Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

### Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

19

#### Table of Contents

Filed Aug 9, 2024.
Source: SEC EDGAR, the filing index for accession 0001477932-24-004635. Last ingested by Listed: Oct 24, 2026, 15:10 ET. No prices; not investment advice.